John H. Barnard
Managing Director |
John is the Founder of Barnard Associates, Inc. (1994) and Barnard Life Sciences (2001). He has 27 years of financial experience at Eli Lilly and Company including Controller of International Operations, Director of Financial Systems, Director of Business Process Reengineering and Controller of DowElanco. Business restructuring experience includes the sale of Elizabeth Arden to Faberge, the creation of DowElanco, Lilly joint ventures in Brazil and Japan, and the formation of numerous other new ventures. Since 1994, John has assisted in the founding of more than a dozen new firms as well as the capitalization and acceleration of many more. John currently serves on the board of several entrepreneurial growth companies including AIT BioSciences, Apexian Pharmaceuticals, Mainstream and YourEncore. He has a BA degree in Psychology from Hanover College, Hanover, Indiana and a MBA degree from Butler University, Indianapolis, Indiana.
|
Mr. Tichenor has over 20 years of experience providing business advisory services to emerging companies. Prior to joining Barnard Associates, Tim served as Director of the Business Development Center for Indiana University. He is familiar with the issues, challenges and the development processes associated with emerging companies. His specialized skills include the ability to assess, develop, and validate strategies and action plans requisite to growing a business. He has filled a variety of interim leadership roles and senior advisory roles for clients in the Barnard Associates portfolio. He has led rounds of financing including as an executive lead and a venture syndicate lead. Tim serves on the board of Grand River Aseptic Manufacturing and YourEncore. Tim holds a BA degree from the University of Saint Francis in Fort Wayne, Indiana and an MBA from the University of Notre Dame.
Tim Tichenor
Managing Director
Tim Tichenor
Managing Director
Dr. Sung brings over a decade of experience in the healthcare sector. Prior to joining Coastview Capital, she was a General Partner at Oxford Bioscience Partners. She has twenty years of direct experience in life science venture capital and has led venture rounds of financing for six transactions, co-founded two biotechnology companies, served on 6 Boards of Directors and served as Chairman of the Board for four biotechnology companies. Previously, she focused on life science and health care investments at Advent International, a global private equity firm that has raised over $6 billion in cumulative capital to date. Dr. Sung received her B.S. in chemistry from The Ohio State University and her Ph.D. in chemistry from Harvard University, where she was a National Science Foundation Pre-Doctoral Fellow.
Stella Sung
Managing Director
Dr. Brennan was previously a General Partner at Oxford Bioscience Partners. Prior to that, he was President and Chief Executive Officer of Gene Logic (NASDAQ: GLGC). During Dr. Brennan’s time at Gene Logic, he built the company from a start-up to a public company that achieved a market capitalization of over $5 billion. He raised three rounds of venture capital and led Gene Logic to an IPO in November, 1997 and a large secondary public offering in January, 2000. Dr. Brennan’s previous experience includes six years in the biopharmaceutical industry, where he has served as Vice President, Business Development for Boehringer Mannheim Therapeutics. Dr. Brennan received a B.S. in Biochemistry, a Ph.D. in neurobiology and a M.D. from the University of Witwatersrand, Johannesburg, South Africa.
Michael Brennan
Managing DIrector
Michael Brennan
Managing DIrector